Among the 344 EGFR TKI-treatedmutant patients, there was no significant difference in treatment response (=0.476) and progression-free survival (=0.401) of EGFR TKI betweenmutation-positive and negative patients. Themutation rate in lung adenocarcinoma with acquired resistance to EGFR TKI is not ...
Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 .....
Compared to other highly incident malignancies (breast, colorectal, prostate, skin, and stomach cancer), lung cancer displays the lowest 5 years survival rate (10%–20%) in most countries among those diagnosed during 2010 through 2014.This is a preview of subscription content, log in via an ...
Pulmonary adenocarcinoma is now the most common type of lung cancer. The morphological and molecular classification of pulmonary adenocarcinoma has undergone significant changes in recent years, resulting in a classification scheme more in tune with patient prognosis and survival. The tumor staging system...
摘要: Background Non-small cell lung cancer (NSCLC) has a 5-year survival of 5–16%. Epidermal growth factor receptor ( EGFR) mutations, in most cases, confer sensitivity to EGFRtyrosine kinase inhibitor... DOI: 10.1007/s11523-018-0594-x 年份: 2018 收藏...
LUAD encompasses 40% of the lung cancer patients and its 5-year overall survival across all subgroups rate averages at only 18%18, highlighting the need of a better understanding of its molecular mechanisms in order to design new therapeutic approaches. First, we analysed MCL-1 genomic gains ...
Epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI) is used for the patients with EGFR-mutant lung cancer. Recently, phase III studies in the patients with EGFR-mutant demonstrated that EGFR-TKI monotherapy improved progression-free survival compared with platinum-doublet ...
Combined analysis with the LIDscore showed that the L-TMB + high-LIDscore group has the worst prognosis, and the median survival of H-TMB + low LIDscore is the longest (Figure S4D). Furthermore, among the 20 genes with the highest mutation rates, mutation rates in the high-...
It remains unclear whether a dominant lung adenocarcinoma that presents with multifocal ground glass opacities (GGOs) should be treated by local therapy. We sought to address survival in this setting and to identify risk factors for progression of unresected GGOs. Methods Retrospective review of 70...
Lung cancer is the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all types of lung cancers.1NSCLC is typically diagnosed at advanced stages, resulting in a poor 5-year survival rate of less than 15%.2Intratumoral ...